---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-060716"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T10:40:00.558981+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Coya reports Q3 net loss $3.4M, cash $10.9M; Phase 2 AD topline due summer 2024

## Summary
- Net loss $3.4M ($0.34/share) vs $4.0M ($1.55/share) in Q3 2022; cash $10.9M up from $5.9M at Dec 2022.
- R&D expenses $1.6M, G&A $2.0M; net loss per share improved due to increase in shares outstanding to 9.95M.
- Completed enrollment (38 patients) in Phase 2 double-blind placebo-controlled trial of LD IL-2 in Alzheimer's; topline data expected summer 2024.
- Plan to submit IND for Phase 2 trial of COYA 302 in ALS in 1H 2024; also licensed exosome engineering technology from Carnegie Mellon.
- Appointed Dieter Weinand to board, Dr. Fred Grossman as President & CMO, and Dr. Merit Cudkowicz as clinical advisor in recent months.

## SEC filing metadata
- accession: 0000950170-23-060716
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000095017023060716/0000950170-23-060716-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000095017023060716/coya-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-060716
- JSON: https://secwatch.observer/filing/0000950170-23-060716.json
- Plain text: https://secwatch.observer/filing/0000950170-23-060716.txt

## Key facts
- Earnings Releases
  Coya Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.
  - Period: third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 8, 2023, Coya Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835022/000095017023060716/0000950170-23-060716-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.